Submissions from 2024
Combination biologics or targeted synthetic disease-modifying anti-rheumatic drugs in the treatment of spondyloarthritis: a systematic literature review., Rand Abedalweli, Michelle Nguyen, and Atul Deodhar
GRAPPA 2023: Major Projects, Key Advances, and Milestones., Gizem Ayan, Sibel Z Aydin, Laura C Coates, Lihi Eder, Dafna D Gladman, Philip S Helliwell, Gurjit S Kaeley, Arthur Kavanaugh, Philip J Mease, Stephen R Pennington, Fabian Proft, Enrique R Soriano, and Oliver FitzGerald
BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studies., Xenofon Baraliakos, Dafna D Gladman, Soumya D Chakravarty, Cinty Gong, May Shawi, Emmanouil Rampakakis, Mitsumasa Kishimoto, Enrique R Soriano, and Philip Mease
Improving the nosology of Long COVID: it is not so simple., Leonard H Calabrese and Philip Mease
GRAPPA 2023 Collaborative Research Network Meeting., Vinod Chandran, Dafna D Gladman, Philip J Mease, Lihi Eder, Stephen R Pennington, Oliver FitzGerald, Christopher Ritchlin, Dan E Webster, Kurt de Vlam, and Wilson Liao
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study., Laura C Coates, Laure Gossec, Miriam Zimmermann, May Shawi, Emmanouil Rampakakis, Natalie J Shiff, Alexa P Kollmeier, Xie L Xu, Peter Nash, Philip J Mease, and Philip S Helliwell
Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study., Laura C Coates, Proton Rahman, Philip J Mease, May Shawi, Emmanouil Rampakakis, Alexa P Kollmeier, Xie L Xu, Soumya D Chakravarty, Iain B McInnes, and Lai-Shan Tam
A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment., Atul Deodhar, Alan J Kivitz, Marina Magrey, Jessica A Walsh, Philip J Mease, Maria Greenwald, Farid Kianifard, Chelsea Elam, Gopi M Bommidi, Adam Winseck, and Lianne S Gensler
Correction: Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical Trial., Kurt de Vlam, Walter P Maksymowych, Gaia Gallo, Proton Rahman, Philip Mease, Venkatesh Krishnan, Conor J McVeigh, Jeffrey Lisse, Danting Zhu, Rebecca J Bolce, and Philip G Conaghan
Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical Trial., Kurt de Vlam, Walter P Maksymowych, Gaia Gallo, Proton Rahman, Philip Mease, Venkatesh Krishnan, Conor J McVeigh, Jeffrey Lisse, Danting Zhu, Rebecca J Bolce, and Philip G Conaghan
Comment on: Effect of gender and age on bDMARD efficacy for axial spondyloarthritis patients: a meta-analysis of randomized controlled trials., Lihi Eder, Jordi Pardo Pardo, Philip Mease, and Lianne S Gensler
Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses., Oliver FitzGerald, Dafna D Gladman, Philip Mease, Christopher Ritchlin, Josef S Smolen, Lu Gao, Yanhua Hu, Miroslawa Nowak, Subhashis Banerjee, and Ian Catlett
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Celebrates Its 20th Anniversary., Dafna D Gladman, Philip S Helliwell, and Philip J Mease
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update., Laure Gossec, Andreas Kerschbaumer, Ricardo J O Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf-Henning Boehncke, Bente Appel Esbensen, Iain B McInnes, Dennis McGonagle, Kevin L Winthrop, Andra Balanescu, Peter V Balint, Gerd R Burmester, Juan D Cañete, Pascal Claudepierre, Lihi Eder, Merete Lund Hetland, Annamaria Iagnocco, Lars Erik Kristensen, Rik Lories, Rubén Queiro, Daniele Mauro, Helena Marzo-Ortega, Philip Mease, Peter Nash, Wendy Wagenaar, Laura Savage, Georg Schett, Stephanie J W Shoop-Worrall, Yoshiya Tanaka, Filip E Van den Bosch, Annette van der Helm-van Mil, Alen Zabotti, Désirée van der Heijde, and Josef S Smolen
Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies., M Elaine Husni, Philip Mease, Joseph F Merola, William Tillett, Nadine Goldammer, Barbara Ink, Jason Coarse, Jérémy Lambert, Vanessa Taieb, and Dafna D Gladman
The Burden of Work Productivity and Activity Impairment in Patients with Psoriasis, Psoriatic Arthritis, Ulcerative Colitis, and Crohn's Disease., Jud C Janak, Anita M Loughlin, Page C Moore, Celeste A Lemay, Philip J Mease, Mark Lebwohl, Joshua R Korzenik, Raymond K Cross, and David Hudesman
Association Between Achievement of Clinical Disease Control and Improvement in Patient-Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT-PsA 1 and 2 Randomized Controlled Trials., Arthur Kavanaugh, Philip Mease, Laure Gossec, Roberto Ranza, Shigeyoshi Tsuji, Kevin Douglas, Michael Lane, Ralph Lippe, Manish Mittal, Tianming Gao, Arathi Setty, Sandra Ciecinski, Daniel Aletaha, and Peter Nash
Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies., Iain B McInnes, Philip Mease, Yoshiya Tanaka, Laure Gossec, M Elaine Husni, Lars Erik Kristensen, Richard B Warren, Barbara Ink, Rajan Bajracharya, Jason Coarse, and Alice B Gottlieb
Effectiveness of bDMARDs in ankylosing spondylitis patients by biologic use: experience from the CorEvitas PsA/SpA Registry., Philip Mease, Taylor Blachley, William N Malatestinic, Leslie R Harrold, Blessing Dube, Jeffrey R Lisse, Rebecca J Bolce, and Theresa M Hunter
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis., Philip Mease, Dafna D Gladman, Joseph F Merola, Peter Nash, Stacy Grieve, Victor Laliman-Khara, Damon Willems, Vanessa Taieb, Adam R Prickett, and Laura C Coates
Navigating the complexity of pain in psoriatic arthritis and axial spondyloarthritis., Philip J Mease
Impact of Disease Factors of Patients with Psoriasis and Psoriatic Arthritis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry., Philip J Mease, Andrew Blauvelt, Adam P Sima, Silky W Beaty, Robert Low, Braulio Gomez, Marie Gurrola, and Mark G Lebwohl
Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies., Philip J Mease, Joseph F Merola, Yoshiya Tanaka, Laure Gossec, Iain B McInnes, Christopher T Ritchlin, Robert B M Landewé, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, and Laura C Coates
Adherence, Persistence, Healthcare Resource Use, and Costs in Tofacitinib-Treated Patients with Psoriatic Arthritis: Data from Two United States Claims Databases., Philip J Mease, Eros Papademetriou, Ravi Potluri, Ekta Agarwal, Joseph C Cappelleri, and You-Li Ling
Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis., Philip J Mease, Soumya Reddy, Sarah Ross, Jeffrey R Lisse, Paulo Reis, Kirstin Griffing, Christophe Sapin, Aisha Vadhariya, and Daniel E Furst
Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison., Philip J Mease, Richard B Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Vanessa Taieb, Jason Eells, and Iain B McInnes
Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison., Philip J Mease, Richard B Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, and Iain B McInnes
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison., Philip J Mease, Richard B Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, and Iain B McInnes
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison., Philip J Mease, Richard B Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, and Iain B McInnes
Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials., Philip Mease, Tatiana Korotaeva, Pavel Shesternya, Muza Kokhan, Anton Rukavitsyn, Dmitry Vasilchenkov, Mohamed Sharaf, Frédéric Lavie, and Atul Deodhar
Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry., Philip Mease, Alexis Ogdie, John Tesser, Natalie J Shiff, Ruizhi Sophia Zhao, Soumya D Chakravarty, Michael Kelleman, Rhiannon Dodge, Robert R McLean, Aaron Broadwell, Arthur Kavanaugh, and Joseph F Merola
Prevalence of Fibromyalgia and Widespread Pain in Psoriatic Arthritis: Association with Disease Severity Assessment in a Large US Registry., Philip Mease, George Reed, Alexis Ogdie, Dimitrios A Pappas, and Joel M Kremer
Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry., Philip Mease, Pamela Young, Lara Fallon, Rajiv Mundayat, Oluwaseyi Dina, Taylor Blachley, Nicole Middaugh, and Alexis Ogdie
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2., Victoria Navarro-Compán, Sofia Ramiro, Atul Deodhar, Philip Mease, Martin Rudwaleit, Christine de la Loge, Carmen Fleurinck, Vanessa Taieb, Michael F Mørup, Ute Massow, Jonathan Kay, and Marina Magrey
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study., Alexis Ogdie, Joseph F Merola, Philip Mease, Christopher T Ritchlin, Jose U Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D Chakravarty, Wayne Langholff, Yanli Wang, Olivia Choi, Yevgeniy Krol, and Alice B Gottlieb
Exploring the complexities of pain phenotypes: OMERACT 2023 chronic pain working group workshop., Tim Pickles, Mary Cowern, Robin Christensen, Sabrina M Nielsen, Lee S Simon, Caitlin M P Jones, Lara J Maxwell, Beverley Shea, Vibeke Strand, Zahi Touma, Karine Toupin-April, Philip Mease, and Ernest Choy
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis., Proton Rahman, Iain B McInnes, Atul Deodhar, Georg Schett, Philip Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, and Dennis McGonagle
Deciphering difficult-to-treat psoriatic arthritis (D2T-PsA): a GRAPPA perspective from an international survey of healthcare professionals., Andre L Ribeiro, Shikha Singla, Vinod Chandran, Nicholas Chronis, Wilson Liao, Christine Lindsay, Enrique R Soriano, Philip Mease, and Fabian Proft
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study., Christopher T Ritchlin, Philip Mease, Wolf-Henning Boehncke, John Tesser, Soumya D Chakravarty, Emmanouil Rampakakis, May Shawi, Elena Schiopu, Joseph F Merola, Iain B McInnes, and Atul Deodhar
Modulation of IL-23 Signaling With Guselkumab in Biologic-Naïve Patients Versus TNF Inhibitor-Inadequate Responders With Active Psoriatic Arthritis., Stefan Siebert, Laura C Coates, Georg Schett, Siba P Raychaudhuri, Warner Chen, Sheng Gao, Loqmane Seridi, Soumya D Chakravarty, May Shawi, Frederic Lavie, Mohamed Sharaf, Miriam Zimmermann, Alexa P Kollmeier, Xie L Xu, Proton Rahman, Philip J Mease, and Atul Deodhar
Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project., Shikha Singla, Andre Ribeiro, Murat Torgutalp, Philip Mease, and Fabian Proft
Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial., Vibeke Strand, Laure Gossec, Laura C Coates, Alexis Ogdie, Jiyoon Choi, Brandon Becker, Joe Zhuo, Thomas Lehman, Miroslawa Nowak, Ayanbola Elegbe, Philip Mease, and Atul Deodhar
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials., Rui Sun, Mercedes Bustamante, Venkatesh Kumar Gurusamy, Mark Lebwohl, Alice B Gottlieb, Philip Mease, Atul Deodhar, Weibin Bao, Meryl Mendelson, Brian Porter, Deepa Chand, and Victor Dong
Imaging in vasculitis., Orrin M Troum, Olga L Pimienta, and Alvin Wells
Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors., Jessica A Walsh, Iris Lin, Ruizhi Zhao, Natalie J Shiff, Laura Morrison, Bruno Emond, Louise H Yu, Samuel Schwartzbein, Patrick Lefebvre, Dominic Pilon, Soumya D Chakravarty, and Philip Mease
Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison., Richard B Warren, Iain B McInnes, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, and Philip Mease
Submissions from 2023
Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons., Nurullah Akkoç, Carlos H Arteaga, Simone E Auteri, Marissa Betts, Kyle Fahrbach, Mindy Kim, Sandeep Kiri, Binod Neupane, Karl Gaffney, and Philip J Mease
Patient clusters identified by machine learning from a pooled analysis of the clinical development programme of secukinumab in psoriatic arthritis, ankylosing spondylitis and psoriatic arthritis with axial manifestations., Xenofon Baraliakos, Effie Pournara, Laura C Coates, Philip Mease, Samad S Jahandideh, and Dafna D Gladman
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis., Gerd R Burmester, Stanley B Cohen, Kevin L Winthrop, Peter Nash, Alan D Irvine, Atul Deodhar, Eduardo Mysler, Yoshiya Tanaka, John Liu, Ana P Lacerda, Hannah Palac, Tim Shaw, Philip J Mease, and Emma Guttman-Yassky
Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study., Laura C Coates, Philip Mease, Dafna D Gladman, Sandra Navarra, Weibin Bao, and Corine Gaillez
Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension., Lihi Eder, Dafna D Gladman, Philip Mease, Remy A Pollock, Rayana Luna, Sibel Z Aydin, Alexis Ogdie, Ari Polachek, David Gruben, Mary Jane Cadatal, Cassandra Kinch, and Vibeke Strand
Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis., Lihi Eder, Sivakami Mylvaganam, Jordi Pardo Pardo, Jennifer Petkovic, Vibeke Strand, Philip Mease, and Keith Colaco
Continuity of Care Within a Single Patient Support Program for Patients with Rheumatoid Arthritis Prescribed Second or Later Line Advanced Therapy., A Mark Fendrick, Philip Mease, Matthew Davis, Pankaj Patel, Wes Matthias, Dominic Nunag, and Manish Mittal
Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis., Alice B Gottlieb, Iain B McInnes, Proton Rahman, Alexa P Kollmeier, Xie L Xu, Yusang Jiang, Shihong Sheng, May Shawi, Soumya D Chakravarty, Frederic Lavie, and Philip J Mease
Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group., Ying-Ying Leung, William Tillett, Maarten de Wit, Ana-Maria Orbai, Laura C Coates, Oliver FitzGerald, Philip S Helliwell, Vibeke Strand, Philip Mease, Niti Goel, Robin Christensen, Joseph F Merola, Christine A Lindsay, Alexis Ogdie, Laure Gossec, and Dafna D Gladman
Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies., Dennis McGonagle, Iain B McInnes, Atul Deodhar, Georg Schett, May Shawi, Soumya D Chakravarty, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Stephen Xu, Christopher T Ritchlin, Proton Rahman, and Phillip J Mease
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)., Iain B McInnes, Akihiko Asahina, Laura C Coates, Robert Landewé, Joseph F Merola, Christopher T Ritchlin, Yoshiya Tanaka, Laure Gossec, Alice B Gottlieb, Richard B Warren, Barbara Ink, Deepak Assudani, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, and Philip Mease
Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study., Philip Mease, Dafna D Gladman, Denis Poddubnyy, Soumya D Chakravarty, May Shawi, Alexa P Kollmeier, Xie L Xu, Stephen Xu, Atul Deodhar, and Xenofon Baraliakos
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment., Philip Mease, Alice B Gottlieb, Alexis Ogdie, Iain B McInnes, Soumya D Chakravarty, Emmanouil Rampakakis, Alexa Kollmeier, Xie L Xu, May Shawi, Frederic Lavie, Mitsumasa Kishimoto, and Proton Rahman
Efficacy and Safety of Tyrosine Kinase 2/Janus Kinase 1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial., Philip Mease, Philip Helliwell, Paula Silwinska-Stanczyk, Malgorzata Miakisz, Andrew Ostor, Elena Peeva, Michael S Vincent, Qiankun Sun, Vanja Sikirica, Randall Winnette, Ruolun Qiu, Gang Li, Gang Feng, Jean S Beebe, and David A Martin
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet's Syndrome., Philip J Mease, Gülen Hatemi, Maria Paris, Sue Cheng, Peter Maes, Wendy Zhang, Rebecca Shi, Andrea Flower, Hernan Picard, and Linda Stein Gold
Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry., Philip J Mease, Alexis Ogdie, John Tesser, Natalie J Shiff, Iris Lin, Soumya D Chakravarty, Michael Kelleman, Rhiannon Dodge, Robert R McLean, Aaron Broadwell, Arthur Kavanaugh, and Joseph F Merola
Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies., Philip J Mease, Ana-Maria Orbai, Oliver FitzGerald, Mohamed Bedaiwi, Dona L Fleishaker, Rajiv Mundayat, Pamela Young, and Philip S Helliwell
Impact of COVID-19 on Patients With Psoriasis or Psoriatic Arthritis., Philip Mease, Peter Nash, Suzanne Grieb, and Vinod Chandran
Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study., Philip Mease, Arathi Setty, Kim Papp, Filip Van den Bosch, Shigeyoshi Tsuji, Mauro Keiserman, Kyle Carter, Yihan Li, Reva McCaskill, Erin McDearmon-Blondell, Peter Wung, and William Tillett
Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study., Philip Mease, Arathi Setty, Kim Papp, Filip Van den Bosch, Shigeyoshi Tsuji, Mauro Keiserman, Kyle Carter, Yihan Li, Reva McCaskill, Erin McDearmon-Blondell, Peter Wung, and William Tillett
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)., Joseph F Merola, Robert Landewé, Iain B McInnes, Philip Mease, Christopher T Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D Gladman, Laure Gossec, Alice B Gottlieb, Diamant Thaçi, Richard B Warren, Barbara Ink, Deepak Assudani, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, and Laura C Coates
Physical Therapist Management of Glenohumeral Joint Osteoarthritis: A Clinical Practice Guideline from the American Physical Therapy Association., Lori A Michener, Jill Heitzman, Laurel D Abbruzzese, Salvador L Bondoc, Kristin Bowne, Phillip Troy Henning, Heidi Kosakowski, Brian G Leggin, Ann M Lucado, and Amee L Seitz
Proceedings of the GRAPPA 2022 Executive Retreat., Beverly Cheok Kuan Ng, Deepak Jadon, Adewale Adebajo, Gizem Ayan, Kristina Callis Duffin, Vinod Chandran, Laura C Coates, Maria Antonietta D'Agostino, Kurt de Vlam, Atul Deodhar, Lihi Eder, Amit Garg, Dafna D Gladman, Niti Goel, Alice B Gottlieb, M Elaine Husni, Arnon Katz, Arthur Kavanaugh, Ennio Lubrano, Philip Mease, Joseph F Merola, Peter Nash, Alexis Ogdie, Stephen R Pennington, Lourdes M Perez-Chada, Fabian Proft, Cheryl F Rosen, Laura Savage, Claudia Goldenstein-Schainberg, Stefan Siebert, Enrique R Soriano, Ingrid Steinkoenig, William Tillett, April W Armstrong, and Oliver FitzGerald
Proceedings of the Collaborative Research Network Meeting at the GRAPPA 2022 Annual Meeting., Beverly Cheok Kuan Ng, Deepak Jadon, Frank Behrens, Maarten de Wit, Oliver FitzGerald, Dafna D Gladman, Philip Mease, Denis O'Sullivan, Stephen R Pennington, Georg Schett, Vinod Chandran, and Kurt de Vlam
Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis., Alexis Ogdie, Dafna D Gladman, Laura C Coates, Effie Pournara, Bhumik Parikh, and Philip Mease
Emotion regulation and the salience network: a hypothetical integrative model of fibromyalgia., Ana Margarida Pinto, Rinie Geenen, Tor D Wager, Mark A Lumley, Winfried Häuser, Eva Kosek, Jacob N Ablin, Kirstine Amris, Jaime Branco, Dan Buskila, João Castelhano, Miguel Castelo-Branco, Leslie J Crofford, Mary-Ann Fitzcharles, Marina López-Solà, Mariana Luís, Tiago Reis Marques, Philip J Mease, Filipe Palavra, Jamie L Rhudy, Lucina Q Uddin, Paula Castilho, Johannes W G Jacobs, and José A P da Silva
Reply to 'Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?'., Ana Margarida Pinto, Rinie Geenen, Tor D Wager, Mark A Lumley, Winfried Häuser, Eva Kosek, Jacob N Ablin, Kirstine Amris, Jaime Branco, Dan Buskila, João Castelhano, Miguel Castelo-Branco, Leslie J Crofford, Mary-Ann Fitzcharles, Marina López-Solà, Mariana Luís, Tiago Reis Marques, Philip Mease, Filipe Palavra, Jamie L Rhudy, Lucina Q Uddin, Paula Castilho, Johannes W G Jacobs, and José A P da Silva
Neurophysiological and psychosocial mechanisms of fibromyalgia: A comprehensive review and call for an integrative model., Ana Margarida Pinto, Mariana Luís, Rinie Geenen, Filipe Palavra, Mark A Lumley, Jacob N Ablin, Kirstine Amris, Jaime Branco, Dan Buskila, João Castelhano, Miguel Castelo-Branco, Leslie J Crofford, Mary-Ann Fitzcharles, Winfried Häuser, Eva Kosek, Philip J Mease, Tiago Reis Marques, Johannes W G Jacobs, Paula Castilho, and José A P da Silva
Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis., Proton Rahman, Wolf-Henning Boehncke, Philip J Mease, Alice B Gottlieb, Iain B McInnes, May Shawi, Yanli Wang, Shihong Sheng, Alexa P Kollmeier, Elke Theander, Jenny Yu, Evan Leibowitz, A Marilise Marrache, and Laura C Coates
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study., Christopher T Ritchlin, Laura C Coates, Iain B McInnes, Philip Mease, Joseph F Merola, Yoshiya Tanaka, Akihiko Asahina, Laure Gossec, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, and Robert Bm Landewé
The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial., Christopher T Ritchlin, Laura C Coates, Philip J Mease, Désirée van der Heijde, Jiao Song, Yusang Jiang, May Shawi, Alexa P Kollmeier, and Proton Rahman
Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies., Emilce E Schneeberger, Gustavo Citera, Peter Nash, Josef S Smolen, Philip Mease, Enrique R Soriano, Claudia Helling, Annette E Szumski, Rajiv Mundayat, and Darío Ponce de León
Project Highlights From the GRAPPA 2022 Annual Meeting: Education Initiatives and Axial Involvement in Psoriatic Arthritis., Murat Torgutalp, Dafna D Gladman, Oliver FitzGerald, Philip Mease, and Denis Poddubnyy
Similarities and differences between axial spondyloarthritis and axial psoriatic arthritis., Weijie Wang, Yung-Heng Lee, James Cheng-Chung Wei, and Philip Mease
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022., Kevin L Winthrop, John D Isaacs, Philip J Mease, Dimitrios T Boumpas, Xenofon Baraliakos, Jacques-Eric Gottenberg, Stefan Siebert, Marta Mosca, Neil Basu, Dana Orange, R Lories, Daniel Aletaha, Iain B McInnes, Tom W J Huizinga, Reinhard E Voll, Ellen M Gravallese, Ferry C Breedveld, and Josef S Smolen
Submissions from 2022
Plain Radiographic Instruments for Structural Damage in Peripheral Joints in Psoriatic Arthritis: A Report From the GRAPPA-OMERACT Working Group., Anna Antony, Richard Holland, Ashish J Mathew, Maria-Antoinetta D'Agostino, Walter P Maksymowych, Philip Mease, Niti Goel, Alexis Ogdie, Laura C Coates, Vibeke Strand, Robin Christensen, Dafna D Gladman, Ana-Maria Orbai, Ying Ying Leung, and William Tillett
2021 GRAPPA Meet the Experts Session: A Summary of Presentations., April W Armstrong, Rasika M Reddy, Oliver FitzGerald, Kristina Callis Duffin, Philip S Helliwell, Philip Mease, Arthur Kavanaugh, Joseph F Merola, William Tillet, and Maarten de Wit
Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial., Xenofon Baraliakos, Effie Pournara, Laure Gossec, Philip J Mease, Roisin White, Eamonn O'Brien, Barbara Schulz, Helena Marzo-Ortega, and Laura C Coates
Novel therapies in axial spondyloarthritis., Mohamad Bittar and Philip Mease
Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results., Laura C Coates, Philip Mease, Andris Kronbergs, Cameron Helt, David Sandoval, So Young Park, Bernard Combe, Peter Nash, and Atul Deodhar
Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results., Laura C Coates, Philip Mease, Andris Kronbergs, Cameron Helt, David Sandoval, So Young Park, Bernard Combe, Peter Nash, and Atul Deodhar
Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis., Laura C Coates, Christopher T Ritchlin, Laure Gossec, Philip S Helliwell, Proton Rahman, Alexa P Kollmeier, Xie L Xu, May Shawi, Chetan S Karyekar, Christine Contré, Wim Noël, Shihong Sheng, Yanli Wang, Stephen Xu, and Philip Mease
Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis., Laura C Coates, Josef S Smolen, Philip Mease, M Elaine Husni, Joseph F Merola, Eric Lespessailles, Mitsumasa Kishimoto, Lisa Macpherson, Andrew J Bradley, Rebecca Bolce, and Philip S Helliwell
Author Correction: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021., Laura C Coates, Enrique R Soriano, Nadia Corp, Heidi Bertheussen, Kristina Callis Duffin, Cristiano B Campanholo, Jeffrey Chau, Lihi Eder, Daniel G Fernández-Ávila, Oliver FitzGerald, Amit Garg, Dafna D Gladman, Niti Goel, Philip S Helliwell, M Elaine Husni, Deepak R Jadon, Arnon Katz, Dhruvkumar Laheru, John Latella, Ying-Ying Leung, Christine Lindsay, Ennio Lubrano, Luis Daniel Mazzuoccolo, Philip J Mease, Denis O'Sullivan, Alexis Ogdie, Wendy Olsder, Penelope Esther Palominos, Lori Schick, Ingrid Steinkoenig, Maarten de Wit, D A van der Windt, Arthur Kavanaugh, and GRAPPA Treatment Recommendations domain subcommittees
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021., Laura C Coates, Enrique R Soriano, Nadia Corp, Heidi Bertheussen, Kristina Callis Duffin, Cristiano B Campanholo, Jeffrey Chau, Lihi Eder, Daniel G Fernández-Ávila, Oliver FitzGerald, Amit Garg, Dafna D Gladman, Niti Goel, Philip S Helliwell, M Elaine Husni, Deepak R Jadon, Arnon Katz, Dhruvkumar Laheru, John Latella, Ying-Ying Leung, Christine Lindsay, Ennio Lubrano, Luis Daniel Mazzuoccolo, Philip Mease, Denis O'Sullivan, Alexis Ogdie, Wendy Olsder, Penelope Esther Palominos, Lori Schick, Ingrid Steinkoenig, Maarten de Wit, D A van der Windt, and Arthur Kavanaugh
The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial., Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Steven Peterson, Prasheen Agarwal, Feifei Yang, Alexa P Kollmeier, Elizabeth C Hsia, Natalie J Shiff, Bei Zhou, Chenglong Han, May Shawi, William Tillett, and Philip Mease
The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial., Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Feifei Yang, Steven Peterson, Prasheen Agarwal, Alexa P Kollmeier, Elizabeth C Hsia, Chenglong Han, Natalie J Shiff, May Shawi, William Tillett, and Philip Mease
Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis., Kurt de Vlam, Philip Mease, Andrew G Bushmakin, Roy Fleischmann, Alexis Ogdie, Valderilio F Azevedo, Joseph F Merola, John Woolcott, Joseph C Cappelleri, Lara Fallon, and Peter C Taylor
Management of Enthesitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations., Lihi Eder, Ashish J Mathew, Philippe Carron, Heidi Bertheussen, Juan D Cañete, May Azem, Andrea Delle Sedie, Carlo Salvarani, Roberto Ranza, Ashley Elliott, Anthony Turkiewicz, Ricardo Acayaba de Toledo, Hulya Bukulmez, Maria S Stoenoiu, Arthur M Mandelin, Michaela Koehm, Chris Lindsay, Evan Siegel, and Philip Mease
Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?' by Braun and Landewé., Dafna D Gladman, Philip Mease, Paul Bird, Enrique R Soriano, Soumya D Chakravarty, May Shawi, Frederic Lavie, Cinty Gong, Evan Leibowitz, Denis Poddubnyy, Lai-Shan Tam, Philip S Helliwell, Arthur Kavanaugh, Atul A Deodhar, Mikkel Østergaard, and Xenofon Baraliakos
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial., Dafna D Gladman, Philip Mease, Paul Bird, Enrique R Soriano, Soumya D Chakravarty, May Shawi, Stephen Xu, Sean T Quinn, Cinty Gong, Evan Leibowitz, Denis Poddubnyy, Lai-Shan Tam, Philip S Helliwell, Arthur Kavanaugh, Atul Deodhar, Mikkel Østergaard, and Xenofon Baraliakos
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data., Alice B Gottlieb, Atul Deodhar, Iain B Mcinnes, Xenofon Baraliakos, Kristian Reich, Stefan Schreiber, Weibin Bao, Kwaku Marfo, Hanno B Richards, Luminita Pricop, Abhijit Shete, Vivek Trivedi, Deborah Keefe, Charis C Papavassilis, Piotr Jagiello, Philemon Papanastasiou, Philip Mease, and Mark Lebwohl
Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial., Philip S Helliwell, Philip Mease, Arthur Kavanaugh, Laura C Coates, Alexis Ogdie, Atul Deodhar, Vibeke Strand, Gregory Kricorian, Lyrica X H Liu, David Collier, and Dafna D Gladman
Efficacy of secukinumab on dactylitis in patients with active psoriatic arthritis from the FUTURE 5 study., Bruce Kirkham, Peter Nash, Delia Reina, Sandra Navarra, Erhard Quebe-Fehling, Corine Gaillez, Carlos Sastre, and Philip Mease
